Cardio Diagnostics addresses cardiometabolic health through its AI driven cardiovascular testing platform, which integrates genetic and epigenetic biomarkers to assess heart attack risk and coronary heart disease (CHD) detection. CHD is a cardiometabolic disease and our technology captures biological signals associated with cardiovascular risk progression, including pathways influenced by lifestyle, environmental exposures, inflammation, vascular dysfunction, and other interconnected cardiometabolic factors.
Because cardiovascular disease and metabolic dysfunction are deeply linked biologically and clinically, our tests can deliver insight beyond traditional screening. Epigenetic markers capture the cumulative impact of lifestyle, environment, behavior, and biological stressors that shape an individual's cardiometabolic risk in real-time, providing a level of precision that standard lipid panels and biometric screenings simply cannot match.
By identifying risk before clinical disease becomes apparent and pinpointing the specific modifiable factors driving early disease, Cardio Diagnostics supports earlier preventive intervention and more personalized cardiovascular care. This upstream approach complements existing wellness, chronic condition, and care management programs employers already have in place, strengthening the broader cardiometabolic strategy without duplicating or replacing what they have already built.
Claimed
